Q3 2018 Earnings Forecast for Halyard Health Issued By KeyCorp (HYH)

Halyard Health (NYSE:HYH) – Stock analysts at KeyCorp decreased their Q3 2018 earnings per share estimates for Halyard Health in a note issued to investors on Thursday, June 21st. KeyCorp analyst M. Mishan now expects that the medical instruments supplier will earn $0.25 per share for the quarter, down from their previous estimate of $0.28. KeyCorp has a “Overweight” rating and a $62.00 price objective on the stock. KeyCorp also issued estimates for Halyard Health’s FY2019 earnings at $1.67 EPS.

Halyard Health (NYSE:HYH) last posted its earnings results on Wednesday, May 2nd. The medical instruments supplier reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.17 by $0.59. Halyard Health had a net margin of 7.72% and a return on equity of 7.90%. The firm had revenue of $156.40 million during the quarter, compared to analysts’ expectations of $155.08 million. During the same period last year, the company posted $0.48 EPS. The company’s quarterly revenue was up 7.3% compared to the same quarter last year.

HYH has been the subject of a number of other reports. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “strong-buy” rating and set a $54.00 price target for the company in a research report on Friday, March 2nd. Stifel Nicolaus lifted their price target on shares of Halyard Health from $52.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, May 3rd. Deutsche Bank lifted their price target on shares of Halyard Health from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, May 3rd. ValuEngine raised shares of Halyard Health from a “hold” rating to a “buy” rating in a research report on Wednesday, February 28th. Finally, Morgan Stanley lifted their price target on shares of Halyard Health from $48.50 to $52.00 and gave the company an “underweight” rating in a research report on Thursday, May 3rd. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $59.80.

Shares of NYSE HYH opened at $59.79 on Monday. Halyard Health has a 1 year low of $38.12 and a 1 year high of $61.52. The stock has a market cap of $2.80 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 3.79 and a beta of 1.67. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.22 and a quick ratio of 2.96.

A number of hedge funds and other institutional investors have recently modified their holdings of HYH. Allianz Asset Management GmbH increased its stake in Halyard Health by 21.0% during the 1st quarter. Allianz Asset Management GmbH now owns 191,450 shares of the medical instruments supplier’s stock valued at $8,822,000 after purchasing an additional 33,242 shares in the last quarter. Principal Financial Group Inc. increased its stake in Halyard Health by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 232,419 shares of the medical instruments supplier’s stock valued at $10,710,000 after purchasing an additional 6,411 shares in the last quarter. Xact Kapitalforvaltning AB increased its stake in Halyard Health by 24.0% during the 1st quarter. Xact Kapitalforvaltning AB now owns 6,716 shares of the medical instruments supplier’s stock valued at $309,000 after purchasing an additional 1,300 shares in the last quarter. Millennium Management LLC increased its stake in Halyard Health by 28.7% during the 1st quarter. Millennium Management LLC now owns 277,691 shares of the medical instruments supplier’s stock valued at $12,796,000 after purchasing an additional 62,002 shares in the last quarter. Finally, Select Equity Group L.P. bought a new stake in Halyard Health during the 1st quarter valued at about $22,064,000. 90.24% of the stock is owned by institutional investors.

About Halyard Health

Halyard Health, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply